Albert J. Robichaud

Albert J. Robichaud joined SAGE Therapeutics as Chief Scientific Officer in 2011, with more than 20 years of drug discovery experience focused primarily in the neuroscience arena. Most recently, he was Vice President of Chemistry and Pharmacokinetic Sciences at Lundbeck USA, where he was responsible for the drug discovery, analytical, computational and pharmacokinetics departments focused on synaptic transmission and neuroinflammation.

Prior to Lundbeck, Dr. Robichaud was Senior Director and Head of the Neuroscience Discovery Chemistry department of Wyeth Research. During his tenure there, his group successfully delivered more than 15 drug candidates into clinical development in a broad range of neuroscience indications.

Dr. Robichaud has co-authored more than 125 manuscripts and abstracts, and is a co-inventor on 45 patents and patent applications.

Dr. Robichaud earned a B.S. in chemistry from Rensselaer Polytechnic Institute, a Ph.D. in organic chemistry from the University of California, Irvine and was an American Chemical Society postdoctoral fellow at Colorado State University.

Albert J. Robichaud is the CSO at SAGE Therapeutics, based in United States, North America. With a background in Biotechnology, Albert J. Robichaud has a rich history of leadership and innovation.Albert J. Robichaud studied B.S. Chemistry at Rensselaer Polytechnic Institute. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.